目次

Table of Contents

Executive Summary
Market Overview

Market Landscape
Market ecosystem
Parent Market
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five Forces Summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Product
Market segments
Comparison by Product
Anticonvulsant drugs - Market size and forecast 2020-2025
Antispastic drugs - Market size and forecast 2020-2025
Anticholinergic drugs - Market size and forecast 2020-2025
NSAIDs - Market size and forecast 2020-2025
Antidepressants and others - Market size and forecast 2020-2025
Market opportunity by Product

Customer landscape
Overview

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape

Drivers, Challenges, and Trends
Market drivers
Market challenges
Market trends

Vendor Landscape
Overview
Landscape disruption
Competitive landscape

Vendor Analysis
Vendors covered
Market positioning of vendors
Abbott Laboratories
AbbVie Inc.
Acorda Therapeutics Inc.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
Johnson and Johnson Inc.
Medtronic Plc
Pfizer Inc.

Appendix
Scope of the report
Currency conversion rates for US$
Research Methodology
List of abbreviations

1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Product - Market share 2020-2025 (%)
22: Comparison by Product
23: Anticonvulsant drugs - Market size and forecast 2020-2025 ($ million)
24: Anticonvulsant drugs - Year-over-year growth 2020-2025 (%)
25: Antispastic drugs - Market size and forecast 2020-2025 ($ million)
26: Antispastic drugs - Year-over-year growth 2020-2025 (%)
27: Anticholinergic drugs - Market size and forecast 2020-2025 ($ million)
28: Anticholinergic drugs - Year-over-year growth 2020-2025 (%)
29: NSAIDs - Market size and forecast 2020-2025 ($ million)
30: NSAIDs - Year-over-year growth 2020-2025 (%)
31: Antidepressants and others - Market size and forecast 2020-2025 ($ million)
32: Antidepressants and others - Year-over-year growth 2020-2025 (%)
33: Market opportunity by Product
34: Customer landscape
35: Market share By Geographical Landscape 2020-2025 (%)
36: Geographic comparison
37: North America - Market size and forecast 2020-2025 ($ million)
38: North America - Year-over-year growth 2020-2025 (%)
39: Asia - Market size and forecast 2020-2025 ($ million)
40: Asia - Year-over-year growth 2020-2025 (%)
41: Europe - Market size and forecast 2020-2025 ($ million)
42: Europe - Year-over-year growth 2020-2025 (%)
43: ROW - Market size and forecast 2020-2025 ($ million)
44: ROW - Year-over-year growth 2020-2025 (%)
45: Key leading countries
46: Market opportunity By Geographical Landscape ($ million)
47: Impact of drivers and challenges
48: Vendor landscape
49: Landscape disruption
50: Industry risks
51: Vendors covered
52: Market positioning of vendors
53: AbbVie Inc. - Overview
54: AbbVie Inc. - Business segments
55: AbbVie Inc. - Key offerings
56: AbbVie Inc. - Key customers
57: AbbVie Inc. - Segment focus
58: Acorda Therapeutics Inc. - Overview
59: Acorda Therapeutics Inc. - Business segments
60: Acorda Therapeutics Inc. - Key offerings
61: Acorda Therapeutics Inc. - Key customers
62: Acorda Therapeutics Inc. - Segment focus
63: Eli Lilly and Co. - Overview
64: Eli Lilly and Co. - Business segments
65: Eli Lilly and Co. - Key offerings
66: Eli Lilly and Co. - Key customers
67: Eli Lilly and Co. - Segment focus
68: F. Hoffmann-La Roche Ltd. - Overview
69: F. Hoffmann-La Roche Ltd. - Business segments
70: F. Hoffmann-La Roche Ltd. - Key offerings
71: F. Hoffmann-La Roche Ltd. - Key customers
72: F. Hoffmann-La Roche Ltd. - Segment focus
73: GlaxoSmithKline Plc - Overview
74: GlaxoSmithKline Plc - Business segments
75: GlaxoSmithKline Plc - Key offerings
76: GlaxoSmithKline Plc - Key customers
77: GlaxoSmithKline Plc - Segment focus
78: GW PharmaceuticalsA, Plc - Overview
79: GW PharmaceuticalsA, Plc - Business segments
80: GW PharmaceuticalsA, Plc - Key offerings
81: GW PharmaceuticalsA, Plc - Key customers
82: GW PharmaceuticalsA, Plc - Segment focus
83: Johnson and Johnson Inc. - Overview
84: Johnson and Johnson Inc. - Business segments
85: Johnson and Johnson Inc. - Key offerings
86: Johnson and Johnson Inc. - Key customers
87: Johnson and Johnson Inc. - Segment focus
88: Medtronic Plc - Overview
89: Medtronic Plc - Business segments
90: Medtronic Plc - Key offerings
91: Medtronic Plc - Key customers
92: Medtronic Plc - Segment focus
93: Pfizer Inc. - Overview
94: Pfizer Inc. - Business segments
95: Pfizer Inc. - Key offerings
96: Pfizer Inc. - Key customers
97: Pfizer Inc. - Segment focus
98: Teva Pharmaceutical Industries Ltd. - Overview
99: Teva Pharmaceutical Industries Ltd. - Business segments
100: Teva Pharmaceutical Industries Ltd. - Key offerings
101: Teva Pharmaceutical Industries Ltd. - Key customers
102: Teva Pharmaceutical Industries Ltd. - Segment focus
103: Currency conversion rates for US$
104: Research Methodology
105: Validation techniques employed for market sizing
106: Information sources
107: List of abbreviations